We examined the expression of potential tumor marker survivin by immunohistochemical staining using antisurvivin antibody (DAKO, Clone 12C4) in a panel of 25 malignant melanomas. In each section, we assessed the percentage of positively stained tumor cells, the intensity of staining and its subcellular localization. Survivin was present in 23 out of 25 cases (92%). Nuclear staining was found in 2 of these 23 cases (8.7%) only, while cytoplasmic staining only was seen in 3 of them (13%). The combined nuclear as well as cytoplasmic localization of survivin was demonstrated in 18 out of 23 cases (78.3%). In 2 cases revealing nuclear staining only, the worse histological features were more pronounced than in 3 cases with cytoplasmic staining only. Our results suggest that nuclear positivity of survivin may correlate with the degree of malignancy. In addition, we conclude that overexpression of survivin involved in the pathogenesis of melanoma represents an important diagnostic marker.
Introduction
The incidence of cutaneous malignant melanoma has dramatically increased over the last decades (Armstrong & Kricker 2001; Jemal et al. 2006) . In developed countries, melanoma represents the leading cause of death among malignant skin tumors. The cause of this malignancy is multi-factorial. Ultraviolet light exposure and genetic susceptibility are thought to be the major etiological and predisposing factors, respectively, which explain the increasing incidence reported recently (Sober et al. 1991; Urist & Karnell 1994) . The overexposure to UV radiation damages the melanocyte DNA. The sequence of carcinogenic steps includes absorption of UV light by nucleotides resulting in formation of cyclobutane pyrimidine dimers. During subsequent cell divisions some of these alterations can escape repair and persist in the genome of daughter cells (Eberle et al. 2007 ). Molecular processes explaining the genesis of malignant melanoma were partially described, but only a small number of involved genes have been characterized. Deregulation occurs in the apoptotic and signal transduction pathways and in the expression of genes which determine matrix digestion and cell adhesion. In addition, defects of certain cell cycle regulators can be involved in the onset and progression of melanoma (Alonso et al. 2004) .
Survivin is one of the eight inhibitor of apoptosis (IAP) proteins comprising a protein family together with c-IAP1, c-IAP2, X-linked inhibitor of apoptosis protein, neuronal apoptosis inhibitory protein, IAP-like protein-2, apollon, and melanoma inhibitor of apoptosis protein/livin (Deveraux & Reed 1999; Amiri & Richmond 2005) .
IAP proteins play a key role in negative regulation of apoptosis (programmed cell death). All the IAP family proteins share 1-3 copies of the baculovirus IAP repeat (BIR) motif consisting of a conserved sequence of about 70 amino acids at their amino terminus. This domain was first identified in baculovirus coded for antiapoptotic proteins. Survivin has a number of distinct features not shared with other IAP members: (i) it is the shortest polypeptide consisting of 142 amino acid residues which possesses a single BIR domain thought to be critical for anti-apoptotic function; (ii) it is undetectable in most terminally differentiated normal cells, but is abundant in embryonic and fetal organs as well as in human malignancies; (iii) the expression of survivin is cell cycle-regulated and occurs in the G2/M phase; (iv) survivin appears to be localized in different subcellular compartments; and (v) it consistently func-tions in both inhibition of apoptosis and regulation of cell division in contrast to other IAP members regularly restricted to one of these two functions (Li 2003 (Li , 2005 Li & Brattain 2006) .
Due to the large quantitative difference in the degree of survivin expression in malignant tumors on the one hand and in corresponding normal tissues on the other hand, survivin appears to represent a promising prognostic marker (Piras et al. 2007 ). In our previous work, we examined the expression of survivin in a panel of dyplastic nevi (Adamkov et al. 2009 ). Here we report on 25 malignant melanomas, in which the subcellular localization of survivin was examined by immunohistochemical staining.
Material and methods
Cases of 25 malignant melanomas were enrolled into this study. The hematoxylin and eosin stained slides from each case were independently reviewed by two pathologists (M. Adamkov, Ľ. Lauko) to ascertain the diagnosis based on morphological and immunohistochemical parameters and correlated with clinical data. The standard diagnostic histomorphological and immunohistochemical criteria, such as assessment of the level invasion (Clark) , tumor thickness (Breslow) and mitotic rate, were applied as described by others (Breslow 1970 (Breslow , 1979 Mihm et al. 1971; Ackerman 1980; Clark et al. 1986 Clark et al. , 1989 Buttner et al. 1995) . Two sections from each paraffin block were subject to immunohistochemical staining for melanoma-associated antigens HMB45 (DAKO, 1:50), S-100 protein (DAKO, 1:40) and melan A (DAKO, 1:50). In addition, three sections four µm thick, obtained from each paraffin block, were stained for survivin protein. To achieve greater adherence of the sections to glass surface, silanized slides (DAKO, Denmark) were used, which had been baked for 2 hours in an oven at 56
Then the sections were deparaffinized in xylene for 20 min, rehydrated in a series of descending ethanol concentrations and washed with phosphate-buffered saline. The endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 30 min. Antigen unmasking was achieved by heating the sections which had been immersed into target solution (DAKO) within a hot water bath (96 • C) for 45 min. Monoclonal mouse anti-survivin antibody (DAKO, Clone12C4, dilution 1:50) was used for staining. After overnight incubation at ambient temperature, the survivin antigen was visualized by means of the labeled streptavidin biotin Vizualization System (DAKO) using 3,3'-diaminobenzidine chromogen as substrate performed according to manufacturer's instructions. All sections were counterstained with Mayer's hematoxylin (DAKO). Negative controls were obtained by simple omitting the primary antibody.
Results

Evaluation of immunohistochemical staining
In each case, the following features were assessed: (i) the intensity of staining; (ii) the relative number of positively stained cells; and (iii) the subcellular localization of survivin antigen.
Survivin was found either in the cytoplasm (C) or nucleus (N) of melanoma cells or in both (NC). To achieve good reproducibility, the parameters in question were evaluated and scored using unified cut-off criteria.
The antigen expression was scored semi-quantitatively as follows: 
Subcellular localization of survivin antigen
As mentioned above, in our panel of 25 melanoma cases, survivin was expressed in 23 samples (92%). The positive cases showed variable subcellular localization. Solely nuclear staining was observed in 2 of 23 cases (8.7%), while cytoplasmic positivity was found in 3 of 23 cases (13%). The combined nuclear as well as cytoplasmic expression of survivin was demonstrated in 18 out of 23 cases (78.3%). All the expression profiles are summarized in Table 1 . At higher magnification, nuclear staining exhibited a punctuate pattern (Fig. 1a,b) ; also the nucleoli often showed an intense survivin immunopositivity (Fig. 1b,c) . The pattern of cytoplasmic staining was either granular (mostly seen), or diffuse or both (Fig. 1b,c) . Because the malignant melanoma cells frequently showed a heterogenic immunoreactivity for survivin, the dominant pattern was used for scoring. The basal epidermal layer of cells proximal to the melanoma lesion exhibited stronger cytoplasmic immunoreactivity than those located in other parts of epidermis.
Discussion
This paper describes the subcellular localization of survivin overexpression in a panel of 25 malignant melanomas. As described above, we found three patterns of immunohistochemical positivity in the nuclei and cytoplasm of melanoma cells. In spite of the small number of our cases with nuclear (Table 1, cases 22 and 23) and/or cytoplasmic reactivity (Table 1 , cases 1-3) for survivin only, we compared some of their histomorphological parameters. Our findings indicate that nuclear survivin positivity is associated with worse histological features. Moreover, 18 out of 23 (78.3%) melanoma cases exhibited a combined nuclear as well as cytoplasmic staining. The latter staining pattern was not described in the melanomas so far. In several studies dealing with survivin antigen as such, its subcellular compartment was not defined (Takeuchi et al. 2005) . Other authors described either the cytoplasmic or the nuclear localization of survivin in melanoma cells (Ding et al. 2006; Piras et al. 2007; Nasr & El-Zammar 2008) . However, the reason for subcellular compartmentalization of survivin in neoplastic tissues is not fully understood. There is growing evidence that several oncogenic pathways are potentially involved in the up-regulation of survivin protein in malignant tumors (Johnson & Howerth 2004) . Conflicting data were re-ported on the role of survivin as prognostic factor. Some authors concluded that increased nuclear survivin expression was associated with an unfavorable prognosis, while small number of papers described nuclear survivin as favorable prognostic feature . In general, survivin expression in cutaneous malignant melanomas has been related to the onset and progression of lesions (Grossman et al. 1999; Alonso et al. 2004; Ding et al. 2006 ). According to Takeuchi et al. (2005) , over-expression of this anti-apoptotic protein was associated with a worse outcome of the melanoma. However, the latter authors did not specify the subcellular localization of survivin in melanoma cells. Recently, the high nuclear expression of survivin was correlated with shorter survival of patients. In contrast, this was not the case with cytoplasmic positivity, which did not predict the clinical outcome (Piras et al. 2007) .
Survivin is the smallest IAP, with only one BIR domain and a C-terminal acid stretch. The most characterized functional units of the IAPs are the BIR domains. Each BIR domain folds into a functionally independent structure and consists of a globular head and an unstructured tail derived from the terminal "linker" region. Despite the overall similarity of the BIR domain structure, the mechanisms of caspase inhibition differ significantly (Xiao-Ming & Zheng 2003) . For example, caspase-9 is inhibited by the BIR3, caspase-3 is inhibited by the BIR 1-2 linker region exclusively, and caspase-7 is inhibited by a combination of the BIR 1-2 linker and the BIR 2 domain (Xiao-Ming & Zheng 2003) . The single BIR domain of survivin inhibits caspases-3 and -7 (Shin et al. 2001) . Any IAP protein contains at least one BIR domain. It seems that some BIR domains are able to inhibit caspase activity by direct binding to the caspase active site, while others require protein to protein interactions (Ambrosini et al. 1997; Deveraux et al. 1997) .
Taking into account the key role of IAPs in the control of programmed cell death, it is not surprising that in a broad spectrum of tumor-biopsies and cancer-cell lines elevated IAP levels were reported (Ambrosini et al. 1997; Tamm et al. 2000; Vucic et al. 2000) . Immunohistochemical patterns of survivin expression provide the most dramatic example of this as testified in a variety of human malignancies and fetal tissues. In contrast, survivin is undetectable in the most of normally differentiated adult cells. Moreover, over-expression of survivin in malignant biopsy samples indicates a poor prognosis, relapse and/or decreased response to chemotherapeutic agents (Mesri et al. 2001 ). The precise mechanism of anti-apoptotic action of survivin is still not fully understood. Several possibilities have been discussed. Survivin seems to exert its activity through the inhibition of caspase activities (Zaffaroni et al. 2005) . Caspases can be inactivated either by over-expression of endogenous caspase inhibitors, by direct mutations within the caspase coding genes or by silencing of the corresponding promoters via methylation (Jones 2001) . This way, survivin functions as an intrinsic regulator of the caspase cascade.
Recent studies have revealed the existence of a mitochondrial pool of survivin (Li & Ling 2006; Piras et al. 2007 ). This plays an important role in the inhibition of mitochondrial apoptotic pathway. In response to a wide range of apoptotic stimuli, mitochondrial survivin is discharged within a few minutes into the cytosol, where via mediator proteins prevents caspase activation and/or otherwise inhibits apoptosis (Dohi et al. 2004 ). Interestingly, survivin was not found in the mitochondria of normal tissue cells suggesting that mitochondrial survivin is exclusively associated with tumor formation (Dohi et al. 2004 ). On the other hand, diverse apoptotic stimuli can activate dual apoptotic pathways. As pointed above, the first one is mediated by caspases, the second one is caspase-independent and associated with nuclear translocation of a mitochondrial apoptosis-inducing factor (AIF). It was shown that survivin expression in melanoma cells may confer protection against both, the caspase-dependent as well as caspase-independent apoptotic pathways. The later may involve suppression of AIF release from the mitochondrial inter-membrane space (Liu et al. 2006 ). These data indicate that endogenous expression of survivin in melanoma cells may contribute to the resistance to apoptosis by a dual mechanism (Liu et al. 2006 ).
As mentioned above, survivin is expressed in malignant tissues and rarely detected in normal differentiated adult ones. This difference makes survivin a promising target for new therapeutic interventions. Numerous experiments which target survivin expression are currently under intense research (Johnson & Howerth 2004) . Basically, there is dual aim in antisurvivin cancer therapy strategies. Firstly, to inhibit growth potential of malignant cells and secondly, to enhance response of malignant cells to apoptosis -inducing therapy.
In conclusion, we demonstrate a combined pattern of survivin expression (nuclear solely, cytoplasmic solely or both) in 25 malignant melanomas. The combined localization of survivin may be considered as an important diagnostic marker in melanoma. Our previous data pointed at usefulness of survivin staining in dysplastic nevi, where nuclear staining might indicate possible progression to melanoma (Adamkov et al. 2009 ). Taken together, survivin seems to represent a candidate protein not only involved in the pathogenesis of melanoma, but also being a diagnostic marker.
